Counsel warns telehealth advertisers that compounded-drug marketing is the enforcement target

A legal compliance alert is warning telehealth advertisers that the FDA's real enforcement target is not compounding itself, but the marketing claims built around it. The alert traces a pattern of federal action against telehealth companies that sell compounded versions of GLP-1 drugs used for weight loss and diabetes ^[1].

On March 3, 2026, the FDA announced it had issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products sold on their websites ^[1]. This was the second wave of such letters since the agency intensified its scrutiny of direct-to-consumer drug advertising in September 2025 ^[1]. The FDA said that in the six months before the alert, it sent more warning letters to pharmaceutical and telehealth firms than in the entire prior decade ^[1]. FDA Commissioner Marty Makary said, "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action" ^[1].

The agency flagged two main problems in the letters. First, some companies implied their compounded products were the same as FDA-approved drugs, including suggesting the products were generic equivalents or had gone through clinical trials, when compounded drugs are not FDA-approved and their safety and effectiveness are not reviewed by the agency ^[1]. Second, some companies branded compounded products with their own name or trademark, which implied the telehealth company itself made the medication, when it likely came from a separate compounding pharmacy ^[1]. Companies that received letters have 15 days to respond or risk legal action, including seizure and injunction ^[1].

This is not the FDA's first round of action in this area. In December 2024, the agency sent warning letters to five companies selling GLP-1 products including semaglutide and tirzepatide labeled as "research use only," after finding that websites and social media made therapeutic claims suggesting the products were meant for human use, and in some cases falsely claimed FDA approval ^[2]. That earlier action set a precedent: the FDA does not need proof that a product is unsafe to act, only evidence that advertising misleads consumers about what the product is or where it came from ^[2].

The compliance alert says enforcement now turns on three things: claims that a compounded drug equals an approved one, implied FDA approval, and implied in-house manufacturing by the telehealth company rather than a separate pharmacy ^[1]. It urges platforms to review landing pages, affiliate marketing copy, and influencer content for these issues ^[1].

Why it matters for patients

Patients using telehealth sites to get compounded semaglutide or tirzepatide may be seeing marketing claims the FDA considers misleading, including suggestions that a compounded product is identical to Ozempic, Wegovy, Mounjaro, or Zepbound, or that it went through the same testing ^[1]. It has not ^[1]. Compounded drugs are not reviewed by the FDA for safety or effectiveness the way approved drugs are ^[1].

The alert also flags that some telehealth companies may blur the line between the company that markets a product and the licensed pharmacy that actually compounds it ^[1]. That distinction matters because state pharmacy laws require clear separation between marketing, prescribing, and dispensing functions, and confusion about who made a drug can complicate accountability if something goes wrong ^[1].

What happens next

Companies that received the March 2026 warning letters had 15 days to respond to the FDA or address the cited problems, meaning most responses were due by late March 2026 ^[1]. The alert notes the FDA has signaled it intends to keep pursuing misleading advertising and inappropriate compounding practices tied to GLP-1 drugs, so further waves of letters are possible, though no specific future date is given in the sources ^[1].